Comparison of glycemic variability in patients with type 2 diabetes given sitagliptin or voglibose: A continuous glucose monitoring-based pilot study

Diabetes Technology and Therapeutics

Volumn 15, Issue 5, 2013, Pages 378-385

  Seo, Chiaki ^a   Sakamoto, Masaya ^a   Nishimura, Rimei ^a   Tsujino, Daisuke ^a   Ando, Kiyotaka ^a   Morimoto, Aya ^a   Utsunomiya, Kazunori ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BIGUANIDE; GLUCOSE; HEMOGLOBIN A1C; SITAGLIPTIN; SULFONYLUREA; VOGLIBOSE;

ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL ARTICLE; CONTINUOUS GLUCOSE MONITORING; CONTROLLED STUDY; DISEASE DURATION; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HOSPITAL DISCHARGE; HUMAN; KINESIOTHERAPY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PILOT STUDY; PRIORITY JOURNAL;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DRUG COMBINATIONS; FEMALE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INOSITOL; JAPAN; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; PILOT PROJECTS; POSTPRANDIAL PERIOD; PYRAZINES; TRIAZOLES;

EID: 84877642015     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2012.0262     Document Type: Article

References (25)

1. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589.
2. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559.
3. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572.
4. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD: Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-139.
5. Nishi Y, Fukushima M, Suzuki H, Mitsui R, Ueda N, Taniguchi A, Nakai Y, Kawakita T, Kurose T, Seino Y, Yamada Y: Insulin secretion and insulin sensitivity in Japanese subjects with impaired fasting glucose and isolated fasting hyperglycemia. Diabetes Res Clin Pract 2005;70:46-52.
6. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A: Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999;22:920- 924.
7. Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria. The Decode Study Group. European Diabetes Epidemiology Group. Diabetes epidemiology: Collaborative analysis of diagnostic criteria in Europe. Lancet 1999;354:617-621.
8. Nakagami T: Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia 2004;47:385-394.
9. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, Ziegelasch HJ, Lindner J: Risk factors for myocardial infarction and death in newly detected NIDDM: The Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996;39:1577-1583.
10. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M: Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial. Lancet 2002;359: 2072-2077.
11. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M: Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: Meta-analysis of seven long-term studies. Eur Heart J 2004;25:10-16.
12. Kawamori R, Tajima N, Iwamoto Y, Kashiwagi A, Shimamoto K, Kaku K: Voglibose for prevention of type 2 diabetes mellitus: A randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 2009;373: 1607-1614.
13. Iwamoto Y, Tajima N, Kadowaki T, Nonaka K, Taniguchi T, Nishii M, Arjona Ferreira JC, Amatruda JM: Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: A randomized, double-blind trial. Diabetes Obes Metab 2010;12:613-622.
14. Cheyne EH, Cavan DA, Kerr D: Performance of a continuous glucose monitoring system during controlled hypoglycemia in healthy volunteers. Diabetes Technol Ther 2002;4:607-613.
15. Boyne MS, Silver DM, Kaplan J, Saudek CD: Timing of changes in interstitial and venous blood glucose measured with a continuous subcutaneous glucose sensor. Diabetes 2003;52:2790-2794.
16. Monnier L, Colette C: Glycemic variability: Should we and can we prevent it? Diabetes Care 2008;31(SUPPL. 2):S150-S154.
17. Goke B, Fuder H, Wieckhorst G, Theiss U, Stridde E, Littke T, Kleist P, Arnold R, Lucker PW: Voglibose (AO-128) is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve. Digestion 1995;56:493-501.
18. Azuma K, Kawamori R, Toyofuku Y, Kitahara Y, Sato F, Shimizu T, Miura K, Mine T, Tanaka Y, Mitsumata M, Watada H: Repetitive fluctuations in blood glucose enhance monocyte adhesion to the endothelium of rat thoracic aorta. Arterioscler Thromb Vasc Biol 2006;26:2275-2280.
19. Risso A, Mercuri F, Quagliaro L, Damante G, Ceriello A: Intermittent high glucose enhances apoptosis in human umbilical vein endothelial cells in culture. Am J Physiol Endocrinol Metab 2001;281:E924-E930.
20. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C: Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006;295:1681-1687.
21. Temelkova-Kurktschiev TS, Koehler C, Henkel E, Leonhardt W, Fuecker K, Hanefeld M: Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care 2000;23:1830-1834.
22. Monnier L, Colette C, Owens DR: Glycemic variability: The third component of the dysglycemia in diabetes. Is it important? How to measure it? J Diabetes Sci Technol 2008;2:1094-1100.
23. Fukase N, Takahashi H, Manaka H, Igarashi M, Yamatani K, Daimon M, Sugiyama K, Tominaga M, Sasaki H: Differences in glucagon-like peptide-1 and GIP responses following sucrose ingestion. Diabetes Res Clin Pract 1992;15:187-195.
24. Narita T, Katsuura Y, Sato T, Hosoba M, Fujita H, Morii T, Yamada Y: Miglitol induces prolonged and enhanced glucagon- like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese type 2 diabetic patients. Diabet Med 2009;26:187-188.
25. Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ: Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001;50:609-613.